Gravity Analytica

Catalyst Pharmaceuticals Recognized as One of North America’s Fastest-Growing Companies on the 2024 Deloitte Technology Fast 500™ List

CPRX 11.25.2024

Full Press Release SEC Filings Our CPRX Tweets

About Gravity Analytica

Recent Filings

Attributes 234% Revenue Growth to Operational Excellence and Strong Commercial Execution

CORAL GABLES, Fla.,Nov. 25, 2024(GLOBE NEWSWIRE) --Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), today announced it ranked number 452 on theDeloitte Technology Fast 500TM, a ranking of the 500 fastest-growing technology media, telecommunications, life sciences, fintech, and energy tech companies inNorth America, now in its 30^thyear. The 2024 Deloitte Technology Fast 500 award winners are selected based on percentage fiscal year revenue growth from 2020 to 2023, for which Catalyst grew 234% during this period.

Catalyst’s President and Chief Executive Officer,Richard J. Daly, credits the team’s operational excellence and strong commercial execution for the 234% revenue growth. He said, “It's an honor to be recognized as one of the fastest-growing companies inNorth Americaacross industry sectors. We remain confident in our ability to execute against our strategy, which includes capitalizing on new opportunities to broaden our rare orphan portfolio with innovative and differentiated products, and we remain steadfast in enhancing our growth potential while prioritizing the needs of our patient communities.”

“For 30 years we’ve been celebrating companies that are actively driving innovation. The software industry continues to be a beacon of growth, and the fintech industry made a strong showing on this year’s list, surpassing life sciences for the first time,” saidSteve Fineberg, Vice Chair,U.S.technology sector leader, Deloitte. “Significantly, we also saw a breakthrough in performance of private companies, with the highest number of private companies named to the list in our program’s history. This year’s winners have shown they have the vision and expertise to continue to perform at a high level, and that deserves to be celebrated.”

“Innovation, transformation and disruption of the status quo are at the forefront for this year’s Technology Fast 500 list, and there’s no better way to celebrate 30 years of program history,” saidChristie Simons, Partner,Deloitte & Touche LLPand industry leader for technology, media and telecommunications within Deloitte’s Audit & Assurance practice. “This year’s winning companies have demonstrated a continuous commitment to growth and remarkable consistency in driving forward progress. We extend our congratulations to all of this year’s winners — it’s an incredible time for innovation.”

Overall, 2024 Technology Fast 500 companies achieved revenue growth ranging from 201% to 153,625% over the three-year time frame, with an average growth rate of 1,981% and median growth rate of 460%.

About the 2024 Deloitte Technology Fast 500Now in its 30^thyear, the Deloitte Technology Fast 500 provides a ranking of the fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies — both public and private — inNorth America. Technology Fast 500 award winners are selected based on percentage fiscal year revenue growth from 2020 to 2023.

In order to be eligible for Technology Fast 500 recognition, companies must own proprietary intellectual property or technology that is sold to customers in products that contribute to a majority of the company’s operating revenues. Companies must have base-year operating revenues of at least US$50,000, and current-year operating revenues of at least US$5 million. Additionally, companies must be in business for a minimum of four years and be headquartered withinNorth America.

AboutCatalyst PharmaceuticalsCatalyst Pharmaceuticals, Inc.(Nasdaq: CPRX) is a biopharmaceutical company committed to improving the lives of patients with rare diseases. With a proven track record of bringing life-changing treatments to the market, we focus on in-licensing, commercializing, and developing innovative therapies. Guided by our deep commitment to patient care, we prioritize accessibility, ensuring patients receive the care they need through a comprehensive suite of support services designed to provide seamless access and ongoing assistance. Catalyst maintains a well-establishedU.S.presence while actively seeking to expand its global commercial footprint through strategic partnerships. Catalyst is headquartered inCoral Gables, FL., and was recognized on the Forbes 2024 list as one of America's most successful small-cap companies.

For more information, please visit Catalyst's website atwww.catalystpharma.com.

About DeloitteDeloitte provides industry-leading audit, consulting, tax and advisory services to many of the world’s most admired brands, including nearly 90% of the Fortune 500® and more than 8,500U.S.-based private companies. At Deloitte, we strive to live our purpose of making animpact that mattersby creating trust and confidence in a more equitable society. We leverage our unique blend of business acumen, command of technology, and strategic technology alliances to advise our clients across industries as theybuild their future. Deloitte is proud to be part of the largest global professional services network serving our clients in the markets that are most important to them. Bringing more than 175 years of service, our network of member firms spans more than 150 countries and territories. Learn how Deloitte’s approximately 460,000 people worldwide connect for impact atwww.deloitte.com.

Forward-Looking StatementsThis press release contains forward-looking statements, as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including those factors described in Catalyst's Annual Report on Form 10-K for the fiscal year 2023 and its other filings with theU.S. Securities and Exchange Commission("SEC"), could adversely affect Catalyst. Copies of Catalyst's filings with theSECare available from theSEC, may be found on Catalyst's website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.

Source:Catalyst Pharmaceuticals, Inc.

Investor ContactMary Coleman, Catalyst Pharmaceuticals, Inc.(305) 420-3200mcoleman@catalystpharma.comMedia ContactDavid Schull, Russo Partners(858) 717-2310david.schull@russopartnersllc.com

Source: Catalyst Pharmaceuticals, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com

Catalyst Pharmaceuticals Recognized as One of North America’s Fastest-Growing Companies on the 2024 Deloitte Technology Fast 500™ List

CPRX 11.25.2024

About Gravity Analytica

Recent News

Recent Filings